Six Breakthroughs Shaping the Future of Diabetes Care

Several members of the AdventHealth Translational Research Institute (TRI) team traveled to New Orleans in June to attend the American Diabetes Association's (ADA) 2026 Scientific Sessions, where more than 12,000 researchers, physicians, and healthcare professionals gathered to share the latest advances in diabetes research. While scientists continue working toward a cure for Type 1 diabetes (T1D), this year's meeting also showcased exciting progress in early detection, diabetes technology, and therapies designed to improve everyday life for people living with the disease. Here are six of the biggest diabetes stories from this year's meeting.

Earlier Detection Is Changing the Future of T1D
One of the strongest themes at this year's meeting was identifying T1D before symptoms develop. Researchers highlighted expanded screening programs that detect diabetes-related autoantibodies, proteins produced by the immune system that signal an autoimmune attack on the insulin-producing beta cells of the pancreas. These markers can appear months, or even years, before blood sugar begins to rise. Identifying people during these early stages allows for closer monitoring and, for some individuals, treatment with disease-modifying therapies that may delay progression to clinical T1D.

The Search for a Functional Cure Continues
Researchers also shared encouraging progress in therapies designed to preserve, replace, or regenerate insulin-producing beta cells. Sessions focused on stem cell-derived islet replacement, immune-based therapies that aim to slow or stop the autoimmune attack, and new approaches to protecting transplanted cells from immune rejection. Although these therapies remain investigational, they represent important steps toward a future where people living with T1D may require little, or potentially no, external insulin.

Artificial Intelligence Is Making Diabetes Care Smarter
Artificial intelligence was a major focus throughout the meeting. Researchers showed how machine learning can analyze glucose readings, insulin doses, meals, physical activity, and other health data to reveal patterns that may be difficult for patients or clinicians to detect. Future uses may include more personalized insulin recommendations, stronger automated insulin delivery systems, earlier identification of people at risk for complications, and decision-support tools that help healthcare providers tailor care to each person.

Oral GLP-1 Medications Move One Step Closer

For years, GLP-1 medications have transformed the treatment of Type 2 diabetes and obesity, but most have required injections. New research presented at ADA highlighted encouraging results for investigational oral GLP-1 medications, including orforglipron, which demonstrated significant improvements in blood sugar control and weight loss in clinical trials. If future studies continue to show positive results, these once-daily pills could offer a more convenient treatment option for many patients.

A New Generation of Diabetes Medications Is Emerging

Researchers also presented exciting data on investigational therapies designed to target multiple metabolic pathways at the same time. One medication receiving considerable attention was retatrutide, which acts on three different hormone receptors involved in metabolism. Early studies suggest these next-generation medications may provide even greater improvements in blood sugar management and weight loss than current therapies, while continuing to explore long-term safety and effectiveness.

Combination Therapies Continue to Expand Possibilities

Scientists are also studying whether combining different hormones can improve diabetes care. New research on CagriSema—a combination of semaglutide and an amylin analogue—demonstrated encouraging improvements in both A1C and body weight. These combination approaches may eventually provide additional treatment options for people whose diabetes is difficult to manage with existing medications alone.

The pace of diabetes research continues to accelerate, with scientists making meaningful progress in prevention, technology, and therapies aimed at changing the course of the disease. Conferences like the ADA Scientific Sessions provide an opportunity for researchers to share discoveries, collaborate across institutions, and translate promising science into better patient care. At the AdventHealth Translational Research Institute, our investigators are proud to be part of that global effort, bringing new knowledge home and helping advance research that offers hope for people living with diabetes today and in the future.

Want to learn more? The ADA Scientific Sessions featured hundreds of presentations covering the latest advances in T1D, Type 2 diabetes, obesity, diabetes technology, and clinical care. Explore additional meeting highlights and scientific coverage on the official ADA Meeting News website: https://www.adameetingnews.org/category/scientific-sessions/2026/session-coverage-2026